The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 23 March 2026•Updated 24 March 2026•

1 min read

Ocugen Reports Positive 12-Month Phase 2 Data for OCU410 Gene Therapy

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Ocugen will host a webcast on March 24, 2026, to discuss Phase 2 ArMaDa trial data.

2 months ago

Version History

1 additional source confirmed this story

Version 22 months ago

Version 12 months ago

What changed: The story was updated from a scheduled announcement to the actual confirmation of positive 12-month topline clinical data and the identification of the therapy as AAV5-RORA.

Ocugen, Inc. (OCGN) has confirmed positive 12-month topline data from its Phase 2 ArMaDa trial evaluating OCU410. This modifier gene therapy, identified as AAV5-RORA, is specifically designed to treat geographic atrophy (GA), a condition expected to see increased prevalence as global populations age. The clinical results demonstrate the therapy's potential in addressing late-stage dry age-related macular degeneration. During a recent presentation, company leadership and key opinion leaders (KOLs) discussed the efficacy and safety profile of the treatment. These positive results serve as a significant catalyst for the biotechnology firm, potentially driving investor confidence and market expectations. The success of OCU410 underscores Ocugen's commitment to developing innovative ophthalmic solutions and expanding its therapeutic portfolio.